Patent details
EP3463315 Title: COMPOSITIONS AND METHODS OF USING NINTEDANIB FOR TREATING OCULAR DISEASES WITH ABNORMAL NEOVASCULARIZATION
Basic Information
- Publication number:
- EP3463315
- PCT Application Number:
- US2017034795
- Type:
- European Patent Granted for LU
- Legal Status:
- Unitary Effect Registered
- Application number:
- EP178072963
- PCT Publication Number:
- WO2017210132
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- COMPOSITIONS AND METHODS OF USING NINTEDANIB FOR TREATING OCULAR DISEASES WITH ABNORMAL NEOVASCULARIZATION
- French Title of Invention:
- COMPOSITIONS ET MÉTHODES D'UTILISATION DE NINTÉDANIB POUR LE TRAITEMENT DE MALADIES OCULAIRES À NÉOVASCULARISATION ANORMALE
- German Title of Invention:
- ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG VON NINTEDANIB ZUR BEHANDLUNG VON AUGENERKRANKUNGEN MIT ABNORMALER NEOVASKULARISATION
- SPC Number:
Unitary Effect
- Unitary Effect Requested:
- Yes
- Unitary Effect Request Filing Date:
- 20/06/2023
- Link to UPP Register:
- European Patent Register
- Unitary Effect Request Withdrawal Date:
- Unitary Effect Status:
- Unitary Effect Registered
- Unitary Effect Acceptance Decision Date:
- 27/06/2023
- Unitary Effect Rejection Decision Date:
- Unitary Effect Date:
- 14/06/2023
- Unitary Effect Registration Date:
- 27/06/2023
- Unitary Effect Re-establishment of rights Filing Date:
- Unitary Effect Re-establishment of rights EPO Decision :
- Unitary Effect Re-establishment of rights EPO Decision Date:
- Explanatory Text UE:
- Safety Net Request Date:
- Safety Net Decision Date:
- Safety Net Decision Outcome:
- SPC Number:
Dates
- Filing date:
- 26/05/2017
- Grant date:
- 14/06/2023
- EP Publication Date:
- 10/04/2019
- PCT Publication Date:
- 07/12/2017
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 14/06/2023
- EP B1 Publication Date:
- 14/06/2023
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 26/05/2037
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 07/06/2023
- Name:
- ADS Therapeutics LLC
- Address:
- 15615 Alton Parkway, Suite 450, Irvine, CA 92618-3308, United States (US)
Inventor
1
- Name:
- NI, Jinsong
- Address:
- United States (US)
2
- Name:
- YANG, Rong
- Address:
- United States (US)
Priority
1
- Priority Number:
- 201662344878 P
- Priority Date:
- 02/06/2016
- Priority Country:
- United States (US)
2
- Priority Number:
- 201662344870 P
- Priority Date:
- 02/06/2016
- Priority Country:
- United States (US)
Classification
- IPC classification:
- A61K 31/506; A61K 9/50; C07D 209/34; A61P 27/06; A61K 9/00; A61K 31/496;
Publication
European Patent Bulletin
1
- Issue number:
- 202324
- Publication date:
- 14/06/2023
- Description:
- Grant (B1)
2
- Issue number:
- 202328
- Publication date:
- 12/07/2023
- Description:
- Application number/publication number of the divisional application (Art. 76) changed
3
- Issue number:
- 202330
- Publication date:
- 26/07/2023
- Description:
- Unitary Effect Request Receipt
4
- Issue number:
- 202330
- Publication date:
- 26/07/2023
- Description:
- Unitary Effect Request Acceptance
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|